Opportunity Information: Apply for PAR 16 212
Apply for PAR 16 212
- The HHS-NIH11 in the education, health sector is offering a public funding opportunity titled "Leveraging Cognitive Neuroscience Research to Improve Assessment of Cancer Treatment Related Cognitive Impairment (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.395,.
- This funding opportunity was created on Apr 21, 2016 and posted on Apr 21, 2016.
- Applicants must submit their applications by Apr 11, 2019. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses, Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The grant opportunity titled "Leveraging Cognitive Neuroscience Research to Improve Assessment of Cancer Treatment Related Cognitive Impairment (R01)" (Funding Opportunity Number PAR-16-212) is a National Institutes of Health (NIH) research project grant announcement aimed at improving how clinicians and researchers measure and understand cognitive changes that can occur after cancer treatment. These treatment-related cognitive effects are commonly described by patients as "chemobrain," though the FOA makes clear that the issue extends beyond traditional chemotherapy alone and includes cognitive changes associated with newer molecularly targeted therapies and hormonal treatments. The central purpose is to support transdisciplinary research that draws on cognitive neuroscience to strengthen or modernize traditional cognitive assessment approaches used with cancer survivors, particularly survivors of non-central nervous system (non-CNS) tumors.
A major emphasis of the FOA is the need to move beyond conventional measurement methods that may miss subtle, domain-specific, or time-dependent cognitive changes. By leveraging cognitive neuroscience, applicants are encouraged to use theory-driven approaches and contemporary tools that can more precisely characterize which cognitive systems are affected, how those effects present in day-to-day functioning, and how patterns of impairment evolve over time. The opportunity highlights both acute changes (those occurring during or shortly after treatment) and late-term changes (those persisting or emerging months to years later). Understanding these trajectories is positioned as essential for building better clinical assessment protocols, which then feed into improved survivorship care planning and follow-up.
The scientific scope is focused on cognitive impairment following exposure to adjuvant cancer therapies used for non-CNS malignancies. In other words, the intent is not to study cognitive outcomes from primary brain tumors or direct CNS-directed therapies, but rather the cognitive impact of systemic therapies used for cancers elsewhere in the body. The FOA explicitly includes adjuvant chemotherapy as well as molecularly targeted treatments and hormonal therapy, reflecting the reality that many modern cancer regimens combine multiple agents and mechanisms, each of which could contribute differently to cognitive outcomes.
From an administrative and eligibility standpoint, this is a discretionary grant mechanism using the NIH R01 funding instrument, which generally supports mature, hypothesis-driven projects with a defined research plan. The sponsoring agency is listed as HHS-NIH (AgencyName: HHS-NIH11), and the associated CFDA numbers are 93.395 (and an additional listing in the provided data). The eligible applicant pool is broad and includes public and private institutions of higher education, nonprofit organizations (both 501(c)(3) and non-501(c)(3)), for-profit organizations (including small businesses), and multiple levels of government entities (state, county, city/township, special district), as well as federally recognized tribal governments, tribal organizations, and public housing authorities/Indian housing authorities. This wide eligibility signals that NIH is open to applications from academic research centers, medical centers, research institutes, and other organizations capable of conducting rigorous human research and cognitive measurement development work.
Key dates in the provided record indicate the FOA was created and posted on April 21, 2016, with an application closing date of April 11, 2019 (listed as both the original and current closing date in the source data). While the data excerpt does not specify an award ceiling or the expected number of awards, the opportunity is structured as an NIH R01, where budgets and project periods are typically justified by scientific need and evaluated through standard NIH peer review criteria.
In practical terms, projects responsive to this FOA would be expected to bring together expertise that may include cognitive neuroscience, neuropsychology, oncology, biostatistics, psychometrics, and survivorship research. The overall goal is not simply to document that cognitive issues exist, but to improve assessment in ways that can translate into clinical practice. The anticipated downstream impact is better identification of survivors experiencing cognitive difficulties, more sensitive tracking of cognitive change over time, and more informative survivorship care plans that account for cognitive health as a component of long-term outcomes after cancer treatment.
Frequently Asked Questions (FAQs)
What is the title of this grant opportunity?
The opportunity is titled "Leveraging Cognitive Neuroscience Research to Improve Assessment of Cancer Treatment Related Cognitive Impairment (R01)."
What is the Funding Opportunity Number (FOA number)?
The Funding Opportunity Number is PAR-16-212.
Which agency is offering this grant?
The sponsoring agency is the National Institutes of Health (NIH), listed as HHS-NIH (AgencyName: HHS-NIH11).
What type of grant mechanism is being used?
This is an NIH research project grant using the R01 funding instrument, which is typically used to support mature, hypothesis-driven projects with a defined research plan.
What is the central purpose of this FOA?
The central purpose is to improve how clinicians and researchers measure and understand cognitive changes that can occur after cancer treatment, using transdisciplinary research that draws on cognitive neuroscience to strengthen or modernize traditional cognitive assessment approaches.
What does the FOA mean by "chemobrain"?
Is this opportunity limited to chemotherapy-related cognitive effects?
No. While adjuvant chemotherapy is included, the FOA explicitly extends to cognitive changes associated with molecularly targeted therapies and hormonal therapy, recognizing that modern cancer regimens often combine multiple agents and mechanisms.
What cancer populations are the focus of this research?
The scientific scope focuses on cognitive impairment following exposure to adjuvant cancer therapies used for non-central nervous system (non-CNS) malignancies (cancers elsewhere in the body).
Are studies on primary brain tumors or CNS-directed therapies included?
No. The FOA indicates the intent is not to study cognitive outcomes from primary brain tumors or direct CNS-directed therapies, but rather cognitive impacts from systemic therapies used for non-CNS cancers.
What kinds of cognitive changes is the FOA interested in?
The FOA emphasizes the need to detect subtle, domain-specific, or time-dependent cognitive changes that conventional measurement approaches may miss, and to more precisely characterize which cognitive systems are affected and how these effects show up in everyday functioning.
Does the FOA address when cognitive changes occur?
Yes. It highlights both acute changes (during or shortly after treatment) and late-term changes (persisting or emerging months to years later), and frames understanding these trajectories as essential for better clinical assessment protocols.
Why does the FOA emphasize cognitive neuroscience?
The FOA encourages theory-driven approaches and contemporary tools from cognitive neuroscience to improve assessment precision and to help clinicians and researchers understand cognitive systems, functional impacts, and how impairment patterns evolve over time.
What is meant by improving or modernizing traditional cognitive assessment approaches?
Based on the FOA description, this means moving beyond conventional measurement methods that may not capture subtle or domain-specific effects, and using cognitive neuroscience-informed approaches and contemporary tools to strengthen how cognitive impairment is assessed in cancer survivors.
What is the intended practical or clinical impact of projects funded under this FOA?
The intended downstream impact includes better identification of survivors experiencing cognitive difficulties, more sensitive tracking of cognitive change over time, and more informative survivorship care plans that incorporate cognitive health into long-term follow-up.
What kinds of expertise or disciplines are expected for responsive projects?
Projects are expected to be transdisciplinary and may involve expertise such as cognitive neuroscience, neuropsychology, oncology, biostatistics, psychometrics, and survivorship research.
Who is eligible to apply?
The eligible applicant pool is broad and includes public and private institutions of higher education; nonprofit organizations (both 501(c)(3) and non-501(c)(3)); for-profit organizations (including small businesses); and multiple levels of government entities (state, county, city/township, special district). It also includes federally recognized tribal governments, tribal organizations, and public housing authorities/Indian housing authorities.
Can for-profit organizations apply?
Yes. For-profit organizations, including small businesses, are listed among the eligible applicants.
Can government entities apply?
Yes. Eligible applicants include state governments, county governments, city or township governments, special district governments, federally recognized tribal governments, and other listed public entities such as public housing authorities/Indian housing authorities.
When was this FOA posted?
The record indicates it was created and posted on April 21, 2016.
What is the application closing date?
The application closing date listed in the provided record is April 11, 2019 (shown as both the original and current closing date in the source data).
Does the provided information include an award ceiling or expected number of awards?
No. The excerpt does not specify an award ceiling or the expected number of awards.
How are budgets and project periods handled for this opportunity?
The description notes that, as an NIH R01, budgets and project periods are typically justified by scientific need and evaluated through standard NIH peer review criteria.
What CFDA numbers are associated with this opportunity?
The associated CFDA number listed is 93.395, with an additional listing noted in the provided data.
What is the overall research emphasis: documenting cognitive problems or improving measurement?
The emphasis is on improving assessment in ways that can translate into clinical practice, not simply documenting that cognitive issues exist.
What survivor group is especially emphasized?
The FOA particularly emphasizes survivors of non-CNS tumors who have been exposed to adjuvant systemic therapies.
Browse more opportunities from the same category: Education, Health
Next opportunity: Notice of Intent: In-Depth Historical Research & Documentation, Phase 3
Previous opportunity: FY 2016 Continuation of the Federal Justice Statistics Program
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 16 212
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 16 212) also looked into and applied for these:
| Funding Opportunity |
|---|
| Extracellular Vesicle Tools, Technologies, and Products for Neuroscience Research (R43/R44) Apply for RFA DA 17 009 Funding Number: RFA DA 17 009 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $150,000 |
| Extracellular Vesicle Tools, Technologies, and Products for Neuroscience Research (R41/R42) Apply for RFA DA 17 008 Funding Number: RFA DA 17 008 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $150,000 |
| Research Answers to NCIs Pediatric Provocative Questions (R21) Apply for PAR 16 217 Funding Number: PAR 16 217 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
| Research Answers to NCIs Pediatric Provocative Questions (R01) Apply for PAR 16 218 Funding Number: PAR 16 218 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Health Services Research on Minority Health and Health Disparities (R21) Apply for PAR 16 222 Funding Number: PAR 16 222 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
| Health Services Research on Minority Health and Health Disparities (R01) Apply for PAR 16 221 Funding Number: PAR 16 221 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| The Role of Mobile Genetic Elements in Cancer (R21) Apply for PAR 16 226 Funding Number: PAR 16 226 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
| NIDA Research Education Program for Clinical Researchers and Clinicians (R25) Apply for PAR 16 224 Funding Number: PAR 16 224 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $350,000 |
| The Role of Mobile Genetic Elements in Cancer (R01) Apply for PAR 16 227 Funding Number: PAR 16 227 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Metabolic Reprogramming to Improve Immunotherapy (R21) Apply for PAR 16 229 Funding Number: PAR 16 229 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
| Non-healing Ulcerative Wounds in Aging (R01) Apply for PA 16 230 Funding Number: PA 16 230 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Metabolic Reprogramming to Improve Immunotherapy (R01) Apply for PAR 16 228 Funding Number: PAR 16 228 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Clinical Sequencing Evidence-Generating Research (CSER2) - Clinical Sites with Enhanced Diversity (U01) Apply for RFA HG 16 011 Funding Number: RFA HG 16 011 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $2,500,000 |
| Clinical Sequencing Evidence-Generating Research (CSER2) - Clinical Sites (U01) Apply for RFA HG 16 010 Funding Number: RFA HG 16 010 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $2,000,000 |
| Neural Regulation of Cancer (R01) Apply for PAR 16 245 Funding Number: PAR 16 245 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Neural Regulation of Cancer (R21) Apply for PAR 16 246 Funding Number: PAR 16 246 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
| Prescription Drug Abuse (R01) Apply for PA 16 233 Funding Number: PA 16 233 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Gene Fusions in Pediatric Sarcomas (R01) Apply for PA 16 251 Funding Number: PA 16 251 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Innovative Approaches to Studying Cancer Communication in the New Media Environment (R01) Apply for PAR 16 249 Funding Number: PAR 16 249 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Gene Fusions in Pediatric Sarcomas (R21) Apply for PA 16 252 Funding Number: PA 16 252 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 16 212", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.